Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib in Relapsed and Refractory Multiple Myeloma
NCT00511238Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2007
- Primary completion
- Nov 2010
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 2
01
Overview
Phase 2, open-label trial of carfilzomib in multiple myeloma (MM) (2 arms), sponsored by Amgen. Primary endpoint: Best Overall Response Rate. Started Aug 2007; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00511238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00511238.